Fintel reports that on July 17, 2023, Morgan Stanley reiterated coverage of Ascendis Pharma A (NASDAQ:ASND) with a Equal-Weight recommendation.
Analyst Price Forecast Suggests 62.98% Upside
As of July 6, 2023, the average one-year price target for Ascendis Pharma A is 141.02. The forecasts range from a low of 89.89 to a high of $196.35. The average price target represents an increase of 62.98% from its latest reported closing price of 86.53.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Ascendis Pharma A is 152MM, an increase of 95.61%. The projected annual non-GAAP EPS is -9.74.
What is the Fund Sentiment?
There are 421 funds or institutions reporting positions in Ascendis Pharma A. This is a decrease of 14 owner(s) or 3.22% in the last quarter. Average portfolio weight of all funds dedicated to ASND is 0.56%, a decrease of 22.73%. Total shares owned by institutions decreased in the last three months by 5.64% to 76,760K shares. 
The put/call ratio of ASND is 0.42, indicating a bullish outlook.
What are Other Shareholders Doing?
Ra Capital Management holds 6,957K shares representing 12.38% ownership of the company. No change in the last quarter.
Artisan Partners Limited Partnership holds 6,845K shares representing 12.18% ownership of the company. In it's prior filing, the firm reported owning 6,920K shares, representing a decrease of 1.10%. The firm decreased its portfolio allocation in ASND by 19.22% over the last quarter.
Janus Henderson Group holds 3,533K shares representing 6.28% ownership of the company. In it's prior filing, the firm reported owning 3,644K shares, representing a decrease of 3.15%. The firm decreased its portfolio allocation in ASND by 21.43% over the last quarter.
T. Rowe Price Investment Management holds 3,473K shares representing 6.18% ownership of the company. In it's prior filing, the firm reported owning 2,828K shares, representing an increase of 18.58%. The firm increased its portfolio allocation in ASND by 0.74% over the last quarter.
Price T Rowe Associates holds 3,370K shares representing 5.99% ownership of the company. In it's prior filing, the firm reported owning 3,710K shares, representing a decrease of 10.09%. The firm decreased its portfolio allocation in ASND by 25.79% over the last quarter.
Ascendis Pharma A Background Information
(This description is provided by the company.)
Ascendis Pharma is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients' lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.
Additional reading:
- Cautionary Note on Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, such as statements regarding our prospective product candida
- Cautionary Note on Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, such as statements regarding our prospective product candida
- Notice to convene Annual General Meeting 2023
- Ascendis Pharma A/S Tuborg Boulevard 12 DK-2900 Hellerup Central Business Registration No. 29 91 87 91 Annual Report 2022 (January 1 – December 31)
- SUSTAINABILITY & PATIENTS | ENVIRONMENTAL, SOCIAL, GOVERNANCE REPORT 2022 P|ESG As part of the Ascendis Pharma A/S 2022 Annual Report, this report outlines the Sustainability and, what we refer to as, Patients|Environmental, Social, and Governance (P
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
